ALK and non-small cell lung carcinoma: Anaplastic lymphoma kinase (ALK) inhibitors are currently the recommended first-line treatment for ALK-rearranged metastatic non-small cell lung cancer (NSCLC) according to the National Comprehensive Cancer Network guidelines.